ASCENTAGE PHARMA GROUP INTERNATIONAL
ASCENTAGE PHARMA GROUP INTERNATIONAL
Your view on AAPG
Overview
What the company does, where it operates, and who runs it.
About ASCENTAGE PHARMA GROUP INTERNATIONAL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dajun Yang
- Headquarters
- CN
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dajun Yang
- Headquarters
- CN
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma.
In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors.
In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions.
Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for ASCENTAGE PHARMA GROUP INTERNATIONAL, and the rating behind it. AAPG last traded at $15.45; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ASCENTAGE PHARMA GROUP INTERNATIONAL. Starting points for ASCENTAGE PHARMA GROUP INTERNATIONAL: EPS -$15.50, beta 0.66 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ASCENTAGE PHARMA GROUP INTERNATIONAL. ASCENTAGE PHARMA GROUP INTERNATIONAL does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ASCENTAGE PHARMA GROUP INTERNATIONAL. Trailing twelve-month EPS for ASCENTAGE PHARMA GROUP INTERNATIONAL stands at -$15.50. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ASCENTAGE PHARMA GROUP INTERNATIONAL. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ASCENTAGE PHARMA GROUP INTERNATIONAL valued side by side against its closest peers. ASCENTAGE PHARMA GROUP INTERNATIONAL is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold ASCENTAGE PHARMA GROUP INTERNATIONAL, and how their positions are changing. At a $1.44B market value, institutional positions materially move ASCENTAGE PHARMA GROUP INTERNATIONAL's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by ASCENTAGE PHARMA GROUP INTERNATIONAL executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming ASCENTAGE PHARMA GROUP INTERNATIONAL. ASCENTAGE PHARMA GROUP INTERNATIONAL is a $1.44B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming ASCENTAGE PHARMA GROUP INTERNATIONAL. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ASCENTAGE PHARMA GROUP INTERNATIONAL. Coverage tracks ASCENTAGE PHARMA GROUP INTERNATIONAL within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.